An observational study in Myeloproliferative Neoplasm, sponsored by University Hospital, Brest. Recruiting at 1 site in France. Open to participants aged 0 Years to 30 Years. Per ClinicalTrials.gov, last updated 2024-12-04.
Sponsored by University Hospital, Brest · Observational
The creation of a national database will provide access to solid data on the diagnosis of myeloproliferative neoplasia for patients under 30, giving a true picture of their care. It will also make it possible to identify the biological samples (histological and molecular) available in routine laboratories, enabling teams of researchers and anatomopathologists to (re)perform certain analyses to re-evaluate diagnoses and search for hitherto unknown molecular prognostic factors.
626 studies on the registry are indexed under Myeloproliferative Disorders; 109 are open to participants now.
This study's planned enrollment of 200 is above the median of 136 across 108 observational studies indexed under Myeloproliferative Disorders.
Browse Myeloproliferative Disorders studies →University Hospital, Brest is the lead sponsor of 594 studies on the registry; 135 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed with non-LMC myeloproliferative neoplasm before age 30 (Polycythemia vera, essential thrombocythemia, primary myelofibrosis, prefibrotic myelofibrosis).
Exclusion Criteria:
Describe the epidemiological characteristics of the study population
Description of MPN subtypes according to age
Time frame: at enrollment
Describe the mutational landscape of these MPNs
Rate of mutations JAK2/CALR/MPL
Time frame: at enrollment
Describe the classical MPN (Myeloproliferative neoplasia) outcomes-1
Incidence of thrombosis
Time frame: At 10 years
Describe the classical MPN outcomes-2
Incidence of myelofibrosis
Time frame: At 10 years
Describe the classical MPN outcomes-3
Incidence of MDS/AML
Time frame: At 10 years
Plan to share: Yes — All collected data that underlie results in a publication
Supporting information: Study protocol
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Brest